Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in combination with Anti-PD-1 Monocolonal Antibody Tislelizumab (BGB-A317) in Pateints with Unresectable Locally Advanced or Metastatic Solid Tumors